How to Manage Estrogen on TRT
Your testosterone goes up, and then your estrogen goes up, and then your doctor prescribes a drug to suppress the estrogen, and now you have two hormones being managed instead of one. That is how most men end up on an aromatase inhibitor, and most of them never needed to be.
To understand why, you need to know what's actually happening in the conversion chain.
Your body makes an enzyme called aromatase, which is the biological machinery that converts testosterone into estradiol. This is not a bug. Men are supposed to aromatize testosterone. Approximately 80% of the estradiol circulating in a man's blood comes from this peripheral conversion process, primarily happening in adipose tissue, with only about 20% coming directly from the testes. That estrogen then goes to work protecting your bones, your cardiovascular system, your brain, and your sexual function. The whole system is designed this way.
So when a TRT patient shows elevated estradiol on a lab panel, the question is not how do we suppress the enzyme. The question is why is the enzyme converting more than it should.
The answer almost always traces back to one of several specific drivers.
The first is body fat. Aromatase is heavily concentrated in adipose tissue, and its gene expression in that tissue is turned up by inflammatory signals, particularly something called TNF-alpha and glucocorticoids, which are stress hormones. As body fat increases, you accumulate more aromatase-expressing tissue, which means more conversion at any given testosterone level. Research from Chand and colleagues in 2015 documented that weight gain and inflammation directly upregulate aromatase expression in male adipose tissue, and more recent work shows that men with obesity have measurably higher aromatase expression in fat tissue compared to lean men. More fat means more enzyme. More enzyme means more estrogen.
The second driver is injection frequency, and this one is purely mechanical.
Aromatase conversion is what's called substrate-driven, meaning the rate of conversion increases when more raw material is available. Testosterone is the substrate. When you inject a full week's dose in a single shot, you create a spike in testosterone that peaks around 24 to 48 hours post-injection. Estradiol trails that peak by roughly one to two days because the aromatase enzyme needs time to process the surge. So you get a large testosterone peak, followed by a large estradiol peak, followed by both hormones declining toward a trough by day seven. The testosterone cypionate half-life is approximately 4.5 days, with a mean residence time of around 8.5 days, so the swing from peak to trough on weekly injections is significant.
Now take that exact same weekly dose and split it into two injections. The peaks are smaller, the troughs are shallower, and the estradiol spikes are reduced accordingly, not because you changed the total amount of testosterone, but because you stopped flooding the aromatase enzyme with a large bolus of substrate all at once. Twice-weekly dosing reduces peak-to-trough variance by roughly 30%. Daily injection flattens the curve further, closer to the body's natural production rhythm of approximately 6 to 7 milligrams per day. To be clear, this intervention has strong pharmacokinetic support and consistent clinical observation behind it, but a dedicated randomized trial measuring estradiol outcomes as the primary endpoint has not been published. The mechanism is sound. The direct trial evidence does not yet exist.
The third major driver is alcohol, which directly increases aromatase activity.
The fourth is insulin resistance, which affects both aromatase expression and something called SHBG, or sex hormone binding globulin, the protein that binds testosterone and holds it inactive in the bloodstream. When SHBG is low, more free testosterone is available for aromatase to work on, which means more conversion even at moderate testosterone levels.
Stress, poor sleep, and systemic inflammation all feed into the same pathway because glucocorticoids and inflammatory cytokines are upstream activators of aromatase gene expression.
Genetics matter too. Individual variation in the CYP19A1 gene, which encodes aromatase, means two men on identical TRT protocols can produce meaningfully different amounts of estradiol.
So when a patient's estradiol comes back elevated, you have a checklist of things that could be driving it, and almost all of them are addressable before you even consider a drug.
The reason this matters so much is what happens when you bypass that checklist and go straight to an aromatase inhibitor.
A 2013 randomized controlled trial published in the New England Journal of Medicine took 400 healthy men between ages 20 and 50, suppressed their natural hormone production with goserelin, then gave them different testosterone doses with or without anastrozole to block aromatization. This design let the researchers isolate what each hormone was doing independently. When estrogen was blocked while testosterone remained present, sexual desire dropped significantly and erectile function declined. Subcutaneous fat area increased two to three times compared to groups with normal estrogen. The study was showing that estrogen does independent work in men that testosterone cannot substitute for.
A separate 2009 trial from Burnett-Bowie and colleagues gave 69 men over age 60 either 1 milligram of anastrozole daily or a placebo for 12 months. Spine bone mineral density decreased significantly in the anastrozole group, with a p-value of 0.0014. The estradiol drop that produced this was not extreme. It moved from approximately 15 picograms per milliliter down to 12. That is a modest reduction, and it was enough to cause measurable bone loss in one year.
This is the trap that plays out in practice. A weekly injection creates an estradiol spike. The symptoms from the spike, water retention, mood changes, nipple sensitivity, prompt an AI prescription. The AI suppresses estrogen too far. Now the patient has joint pain, erectile dysfunction, and mood disruption from low estrogen. The provider adjusts the AI dose. The patient oscillates between too high and too low. Two drugs are now managing a problem that started with one variable: peak testosterone concentration.
If you are on TRT and your estradiol is elevated, the first move is an accurate test. The standard immunoassay used for women can cross-react with other steroids and return inflated numbers in men. The accurate measurement is an LC-MS/MS test, which stands for liquid chromatography tandem mass spectrometry, and it is the gold standard for male estradiol measurement. If that number is genuinely high, look at injection frequency first, then body composition, then alcohol, sleep, stress, and metabolic health. A reasonable estradiol target for most men on standard TRT doses is somewhere in the 20 to 35 picogram per milliliter range, though men on higher doses may feel well with levels between 40 and 60.
An aromatase inhibitor does have a place. Some men have genetic expression of the CYP19A1 enzyme that produces conversion rates no lifestyle intervention will fully correct. But that is the edge case, not the starting point.
The reason estrogen keeps getting treated like an enemy on TRT is that it responds to testosterone in ways that look like problems, and the drug that suppresses it is easy to prescribe. But estrogen is not responding incorrectly. The inputs are wrong. Fix the inputs first.
References
- Finkelstein JS, Lee H, Burnett-Bowie SA, et al. 2013. Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men. New England Journal of Medicine, 36911, 1011-1022. Source
- Burnett-Bowie SM, McKay EA, Lee H, Leder BZ. 2009. Effects of Aromatase Inhibition on Bone Mineral Density and Bone Turnover in Older Men with Low Testosterone Levels. Journal of Clinical Endocrinology and Metabolism, 9412, 4785-4792. Source
- Pastuszak AW, et al. 2022. Pharmacokinetics of Testosterone Cypionate Delivered via Subcutaneous Autoinjector. Andrology. Source
- Chand AL, et al. (2015). Weight gain and inflammation regulate aromatase expression in male adipose tissue. Journal of Steroid Biochemistry and Molecular Biology.
- Bhasin S, Brito JP, Cunningham GR, et al. (2018). Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. JCEM, 103(5), 1715-1744.
Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness
If this is the kind of information you want access to on a daily basis, the community is free and there are full courses on training, nutrition, hormones, and supplementation inside. You can ask questions and post your own labs and get feedback from me and from the community.